On August 25-26, the U.S. Drug Enforcement Administration (DEA) followed up on two Federal Register notices published on July 1 that signaled its intent to temporarily place several synthetic alkaloids associated with Mitragyna speciosa (commonly known as kratom leaf or kratom) in Schedule I of the Controlled Substances Act (CSA). One notice concerned three synthetic…
Atai Life Sciences’ stock dips after announcing Phase 1 data
Atai Life Sciences (Nasdaq:ATAI) announced inconclusive data regarding the effects of the kratom-derived compound KUR-101 on respiration in a Phase 1 study. The company’s stock was down about 9% in mid-day trading, trading at $2.77. The drug candidate yielded dose-dependent analgesic effects in Part 1 of the study, which assessed the safety and efficacy of various dose…
FDA seeks comments on psychotropic substances, including kratom
The FDA has announced that it is looking for feedback on seven drugs, including kratom (mitragynine, 7-hydroxymitragynine), a popular recreational drug that remains legal at the federal level. FDA has warned consumers not to use kratom, which targets opioid receptors in the brain. There are no FDA-approved uses for the psychotropic herbal extract. WHO had reached…


